Skip to content
Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Al Sayed M, Burney I.
BMC Cancer. 2021 Dec 20;21(1):1350. doi: 10.1186/s12885-021-09094-8.
Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
Powell CB, Laurent C, Garcia C, Hoodfar E, Karlea A, Kobelka C, Lee J, Roh J, Kushi LH.
Clin Genet. 2021 Dec 20. doi: 10.1111/cge.14100. Epub ahead of print.
Epidemiologic evidence of exposure to polycyclic aromatic hydrocarbons and breast cancer: A systematic review and meta-analysis.
Gamboa-Loira B, López-Carrillo L, Mar-Sánchez Y, Stern D, Cebrián ME.
Chemosphere. 2021 Dec 17:133237. doi: 10.1016/j.chemosphere.2021.133237. Epub ahead of print.
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer.
Navitski A, Al-Rawi DH, Liu Y, Rubinstein MM, Friedman CF, Rampal RK, Mandelker DL, Cadoo K, O'Cearbhaill RE.
Gynecol Oncol Rep. 2021 Oct 5;38:100873. doi: 10.1016/j.gore.2021.100873. eCollection 2021 Nov.
The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC).
Rose PG, Yao M, Chambers LM, Mei L, Le P.
Gynecol Obstet (Sunnyvale). 2021;11(9):570. Epub 2021 Oct 7.
To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
Rose PG, Chambers LM, Kuznicki M.
Gynecol Obstet (Sunnyvale). 2021;11(7):561. Epub 2021 Aug 3.
Post navigation